BNT162c(2): Self-Amplifying RNA (saRNA); the Next Horror By Brian Simpson
Just in case you thought the Dr Frankensteins could not top mRNA vaxxes, here comes the next invention, self-amplifying RNA, which as Dr Rose argues, will open a whole new bag of horrors. Big pHARMA can’t wait to get this into new vaxxes, and into deltoid muscles.
“So the claim is that this self amplifying messenger RNA is awesome because you need to inject less of it. But here’s the thing: it encodes its own replicase enzyme - it makes copies of the RNA (whatever it is) once inside the cells. Does that sound problematic to you? To me, it does. And here’s why. If the other genes in the mRNA encode destructive proteins (like the modified mRNA of the SARS-nCoV-2 spike protein), then… for one, how will it ever be possible to turn off these self-amplifying RNAs? Are the replicases self-limiting?
If you ask me, the people developing and promoting this technology are concerned only about profit, ‘cost’ and initial dose. They claim that adverse event occurrences are proportional to the initial dose of RNA. Hmm. Anna claims in the interview that the menstrual cycle disruptions induced by the COVID-19 mRNA injectable products are temporary, and can also be brought on by viral infections. She also claimed that the vaccinated people won’t get severe COVID-19 in the context of hospitalization. Really? I missed out on that point in the interview. She was pretty sure that since most of the people in Israel had been injected, that this would explains why the majority of COVID-19 hospitalizations were in the context of the injected. But then, if the shots were meant to reduce severity, why would they ending up in the hospital?
So as we all know by now, the messenger RNA in the COVID-19 Pfizer/BioNTech and Moderna products, is the mode of delivery of information for the cells in our bodies to make lots and lots of modified spike proteins. That’s what these folks are now calling ‘conventional’ mRNA.1 Well now! That was fast. Now it’s a CONVENTION? Aaaaaaaaaaalrightttttttyyyyy thennnn.
So this saRNA has been on the schedule the whole time. They didn’t even anticipate the possibility that the ‘conventional’ mRNA would be a failure, because, if it was, imagine how bad that would be for the schedule! And guess what, it’s being trialed now.
What do you want to bet that those trial participants have NO IDEA that they are being injected with self-amplifying RNA? This study is active with ‘estimated’ primary completion date April, 2023 (final data collection date for primary outcome measure).
- BNT162c2 will be administered using a Prime/Boost (P/B) regimen. The vaccine BNT162c2 will also be administered using a Single dose (SD) regimen.
- Experimental: BNT162c2 (P/B) - Part A 18-55 years of age
- Escalating dose levels
- Intervention: Biological: BNT162c2.
- The primary endpoint is 21 days post injection.
- Actual Enrollment (submitted: January 12, 2022): 512
I find two things to be insane:
- That I haven’t heard that the saRNAs are already being trialed and
- That there is no mention of self-amplifying mRNAs in the clinical trial data sheet. There is, owever, a very long exclusion criteria list and an informed consent clause as part of it.
Inclusion criteria: Have given informed consent by signing the informed consent form (ICF) before initiation of any trial-specific procedures.
What do you want to bet that this document that required signing said nothing of self-amplifying RNAs?
I put this together today when I opened up the FOIA document attached at the top of this article. I had received an email on June 9th, 2022 (10 days ago) that was addressed to myself and Robert Malone as to what the ‘BNT162c2’ was. I had told the addresser that I hadn’t heard of it before and Robert pointed us both to the clinical trial with ClinicalTrials.gov Identifier: NCT04380701.
But, I still didn’t know what it was. Maybe it had a different LNP? Nope.
It’s a completely different type of technology. Again.
What’s the encoded antigen? We’re not going to tell you! But we are going to insist that you get injected with it. Or, no soup for you.
Even though there are peer-reviewed studies on this technology, I cannot stress this point enough: WE NEED LONG TERM DATA WHEN IT COMES TO NEW TECH. Not 21 days. Not 365 days. We need years. We are NOT in an emergency and therefore, we have the time to explore the safety and efficacy of saRNA technology carefully and properly. Like we should have been doing the whole time with our now magically ‘conventional’ mRNA tech.
Sorry, I have to include this screenshot. This is just too precious. It’s so safe. Just inject me now. Wait, I can’t see! Everything turned black! Kind of like the safety data redaction for the product. (Sorry for the very dark humor. Sorry. I did it again.)
Oh and they mention in section 7.2 Posology and method of administration, that ‘the vaccine should not be injected into areas where there may be a major nerve trunk’. Ok. Good to know.
And this literally made me LAUGH OUT LOUD. Look at this.
7.11.2 Non-clinical findings of note
All tested non-clinical and clinical vaccine candidates were immunogenic to highly immunogenic in non-clinical models. The available data demonstrate that BNT162b1, BNT162b2, BNT162b3, and BNT162c2 are capable of inducing robust immune responses in mice, (except for BNT162c2) rats and NHPs.
Why would they include BNT162c2 in this list if it’s not in the list?
So when you order a cheeseburger, because you love cheese, and it comes without cheese on it and you complain, they yell at you that ‘cheeseburger’ is just a word and had nothing to do with a burger having cheese on it, what are you to do? Same logic, yeah?
If we have not learned yet that we need to be cautious with gene-based therapies, then, you know what? I just don’t know what to say.”
If normal mRNA vaxxes have proved so problematic what will the new ones ring in?”